Tempest Therapeutics, Inc. Stock-Based Compensation
Tempest Therapeutics, Inc. (TPST) reported Stock-Based Compensation of -$117.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was -$117.00K, a 110.71% decline year-over-year.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $226.00K, a 83.73% decline year-over-year.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $576.00K, a 56.72% decline year-over-year.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $61.00K, a 95.43% decline year-over-year.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $3.12M, a 41.20% decline from fiscal 2024.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $5.30M, a 108.29% increase from fiscal 2023.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $2.55M, a 63.10% increase from fiscal 2022.
- Tempest Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $1.56M, a 41.27% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$117.00K 10-Q · filed 2026-08-13 | $109.00K 10-Q · filed 2026-08-13 | $685.00K derived: sum of 3 quarters · filed 2026-08-13 | $746.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $226.00K 10-Q · filed 2026-05-14 | $802.00K derived: sum of 2 quarters · filed 2026-05-14 | $863.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.96M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $576.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $637.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.73M derived: sum of 3 quarters · filed 2026-08-13 | $3.12M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $61.00K 10-Q · filed 2025-11-05 | $1.15M derived: sum of 2 quarters · filed 2026-08-13 | $2.54M 10-Q · filed 2025-11-05 | $3.87M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.09M 10-Q · filed 2026-08-13 | $2.48M 10-Q · filed 2026-08-13 | $3.81M derived: sum of 3 quarters · filed 2026-08-13 | $5.15M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.39M 10-Q · filed 2026-05-14 | $2.72M derived: sum of 2 quarters · filed 2026-05-14 | $4.05M derived: sum of 3 quarters · filed 2026-05-14 | $5.37M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.67M derived: sum of 2 quarters · filed 2026-03-30 | $3.98M derived: sum of 3 quarters · filed 2026-03-30 | $5.30M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.33M 10-Q · filed 2025-11-05 | $2.65M derived: sum of 2 quarters · filed 2025-11-05 | $3.97M 10-Q · filed 2025-11-05 | $5.07M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $1.32M 10-Q · filed 2025-08-11 | $2.64M 10-Q · filed 2025-08-11 | $3.73M derived: sum of 3 quarters · filed 2025-08-11 | $4.30M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-13 | $2.42M derived: sum of 2 quarters · filed 2025-05-13 | $2.98M derived: sum of 3 quarters · filed 2025-05-13 | $3.42M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.66M derived: sum of 2 quarters · filed 2025-03-27 | $2.10M derived: sum of 3 quarters · filed 2025-03-27 | $2.55M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $563.00K 10-Q · filed 2024-11-12 | $1.00M derived: sum of 2 quarters · filed 2024-11-12 | $1.45M 10-Q · filed 2024-11-12 | $1.88M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $440.00K 10-Q · filed 2024-08-08 | $886.00K 10-Q · filed 2024-08-08 | $1.31M derived: sum of 3 quarters · filed 2024-08-08 | $1.75M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $446.00K 10-Q · filed 2024-05-09 | $874.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.31M derived: sum of 3 quarters · filed 2024-05-09 | $1.68M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $866.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.23M derived: sum of 3 quarters · filed 2024-03-19 | $1.56M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $438.00K 10-Q · filed 2023-11-08 | $805.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.13M 10-Q · filed 2023-11-08 | $1.41M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $367.00K 10-Q · filed 2023-08-10 | $695.00K 10-Q · filed 2023-08-10 | $973.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.27M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $328.00K 10-Q · filed 2023-05-10 | $606.00K derived: sum of 2 quarters · filed 2023-05-10 | $902.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.31M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $574.00K derived: sum of 2 quarters · filed 2023-03-22 | $985.00K derived: sum of 3 quarters · filed 2023-03-22 | $1.10M 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | $296.00K 10-Q · filed 2022-11-08 | $707.00K derived: sum of 2 quarters · filed 2022-11-08 | $827.00K 10-Q · filed 2022-11-08 | $959.00K derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $411.00K 10-Q · filed 2022-08-15 | $531.00K 10-Q · filed 2022-08-15 | $663.00K derived: sum of 3 quarters · filed 2022-08-15 | $754.00K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $120.00K 10-Q · filed 2022-05-13 | $380.00K 10-Q · filed 2021-05-13 | $252.00K derived: sum of 2 quarters · filed 2022-05-13 | $343.00K derived: sum of 3 quarters · filed 2022-05-13 | $570.00K derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $223.00K derived: sum of 2 quarters · filed 2022-03-29 | $450.00K derived: sum of 3 quarters · filed 2022-03-29 | $453.00K 10-K · filed 2022-03-29 | $4.24M 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $91.00K 10-Q · filed 2021-11-10 | $1.09M 10-Q · filed 2020-11-09 | $318.00K derived: sum of 2 quarters · filed 2021-11-10 | $321.00K 10-Q · filed 2021-11-10 | $3.15M 10-Q · filed 2020-11-09 | $2.58M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $227.00K 10-Q · filed 2021-08-12 | $980.00K 10-Q · filed 2020-08-10 | $230.00K 10-Q · filed 2021-08-12 | $2.06M 10-Q · filed 2020-08-10 | $2.49M derived: sum of 3 quarters · filed 2021-08-12 | $3.69M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $1.08M 10-Q · filed 2021-05-13 | $2.27M derived: sum of 2 quarters · filed 2021-05-13 | $3.46M derived: sum of 3 quarters · filed 2021-05-13 | $4.46M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $2.38M derived: sum of 2 quarters · filed 2021-03-29 | $3.38M derived: sum of 3 quarters · filed 2021-03-29 | $4.32M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $1.20M 10-Q · filed 2020-11-09 | $2.19M derived: sum of 2 quarters · filed 2020-11-09 | $3.13M 10-Q · filed 2020-11-09 | $3.80M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $994.00K 10-Q · filed 2020-08-10 | $1.93M 10-Q · filed 2020-08-10 | $2.60M derived: sum of 3 quarters · filed 2020-08-10 | $3.02M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $939.00K 10-Q · filed 2020-05-08 | $1.61M derived: sum of 2 quarters · filed 2020-05-08 | $2.03M derived: sum of 3 quarters · filed 2020-05-08 | $2.19M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $1.09M derived: sum of 2 quarters · filed 2020-03-11 | $1.25M derived: sum of 3 quarters · filed 2020-03-11 | $1.43M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $423.00K 10-Q · filed 2019-11-13 | $582.00K derived: sum of 2 quarters · filed 2019-11-13 | $759.00K 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $159.00K 10-Q · filed 2019-08-12 | $336.00K 10-Q · filed 2019-08-12 | ||||||
| 2018-03-31 | $177.00K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $762.00K 10-K · filed 2019-04-01 | |||||||
| 2013-09-30 | $200.00K 10-Q · filed 2013-11-13 | $200.00K 10-Q · filed 2013-11-13 | ||||||
| 2012-09-30 | $300.00K 10-Q · filed 2012-11-13 | $599.10K derived: sum of 2 quarters · filed 2012-11-13 | $859.00K 10-Q · filed 2012-11-13 | |||||
| 2012-06-30 | $299.10K 10-Q · filed 2012-08-14 | $558.48K 10-Q · filed 2012-08-14 | ||||||
| 2011-09-30 | $30.00K 10-Q · filed 2012-11-13 | $38.50K 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |